Mangalam Drugs & Organics Ltd
Company Profile
Business description
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
Contact
P. D'Mello Road
Rupam Building, 3rd Floor, No. 239
Near General Post Office
MumbaiMH400001
INDT: +91 2222616200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
480
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
stocks
Major ASX miner remains overvalued following production update
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.90 | 33.40 | 0.37% |
| CAC 40 | 8,346.21 | 6.10 | 0.07% |
| DAX 40 | 24,875.86 | 29.17 | 0.12% |
| Dow JONES (US) | 51,839.26 | 307.16 | -0.59% |
| FTSE 100 | 10,537.43 | 12.67 | 0.12% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,508.07 | 12.17 | -0.05% |
| Nikkei 225 | 66,232.19 | 2,091.07 | 3.26% |
| NZX 50 Index | 13,656.03 | 40.00 | -0.29% |
| S&P 500 | 7,443.28 | 14.41 | -0.19% |
| S&P/ASX 200 | 8,793.30 | 36.30 | 0.41% |
| SSE Composite Index | 3,864.37 | 68.09 | 1.79% |